TITLE

Pitavastatin Tablets (Livalo®)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
October 2009
SOURCE
Internal Medicine Alert;10/15/2009, Vol. 31 Issue 19, p149
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information on the seventh HMG-CoA reductase inhibitor pitavastatin for patients with primary hyperlipidemia and mixed dyslipidemia. It is stated that pitavastatin decreases the level of total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG). It adds that the suggested starting dose for the drug is 2 milligrams per day in which the dosage may be increased if lowering of LDL-C is insufficient.
ACCESSION #
44960612

 

Related Articles

  • An Equation to Estimate the Concentration of Serum Apolipoprotein B. You-Cheol Hwang; Hong-Yup Ahn; Woo Je Lee; Cheol-Young Park; Sung-Woo Park // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Background: Several large prospective studies have demonstrated that apolipoprotein B (apoB) has greater value in predicting cardiovascular risk than any other lipid measurements. Currently, however, serum apoB levels are not routinely measured, because of the additional cost. The aim of this...

  • Pharmacotherapy of Mixed Hyperlipidemia with Ezetimibe-Fenofibrate Combination Therapy. Farnier, Michel // Clinical Medicine: Therapeutics;2009, Issue 1, p1703 

    Mixed hyperlipidemia is a frequent atherogenic dyslipidemia characterized by elevated triglycerides, low HDL cholesterol levels, and excess of small, dense LDL particles, often with elevated apolipoproteinB and non-HDL cholesterol concentrations. Although statins are the drug of first choice,...

  • MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Soh, James; Iqbal, Jahangir; Queiroz, Joyce; Fernandez-Hernando, Carlos; Hussain, M Mahmood // Nature Medicine;Jul2013, Vol. 19 Issue 7, p892 

    Hyperlipidemia is a risk factor for various cardiovascular and metabolic disorders. Overproduction of lipoproteins, a process that is dependent on microsomal triglyceride transfer protein (MTP), can contribute to hyperlipidemia. We show that microRNA-30c (miR-30c) interacts with the 3′...

  • Dyslipidaemia: integration between primary and secondary care. Skinner, Jane S. // Clinical Medicine;Jun2011, Vol. 11 Issue 3, p258 

    The article offers an overview of a session on dyslipidaemia that was covered of a conference organized by the British Geriatrics Society and the Royal College of Physicians (RCP) that was held on June 8, 2010. It explores the influence of lipid lowering drugs on the primary care of patients...

  • Triglyceride-to-HDL Cholesterol Ratio in the Dyslipidemic Classification of Type 2 Diabetes. Wägner, Ana María; Pérez, Antonio; Sánchez-Quesada, Jose Luis; Ordóñez-Llanos, Jordi // Diabetes Care;Jul2005, Vol. 28 Issue 7, p1798 

    Discusses research on the evaluation of triglyceride-to-high density lipoprotein (HDL) cholesterol ratio, non-HDL cholesterol and apolipoprotein B to predict low-density lipoprotein (LDL) phenotype and to assess them in the risk classification of patients with type 2 diabetes. Total number of...

  • HIGH CARDIOVASCULAR RISK IN PATIENTS WITH PSORIASIS. Arora, Megha Kataria; Seth, Shashi; Seth, Mamta // International Journal of Pharma & Bio Sciences;Jan-Mar2011, Vol. 2 Issue 1, pB155 

    Objective Dyslipidemia is one of the important risk factor for cardiovascular disease so present study was planned to evaluate risk of cardiovascular disease in patients with psoriasis. Design and Methods It was a hospital based case control study performed in the 85 patients of psoriasis with...

  • COMMENTARY: Ezetimibe plus simvastatin lowered lipid levels more than simvastatin monotherapy in primary hypercholesterolemia. Bronson, David L // ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p16 

    The article reports that ezetimibe plus simvastatin lowered lipid levels more than simvastatin monotherapy in primary hypercholesterolemia. Ezetimibe is a novel lipid-lowering agent that works by blocking intestinal cholesterol absorption. It is most reassuring to see that the combination of...

  • Reduced Serum Levels of Triglyceride, Very Low Density Lipoprotein Cholesterol and Apolipoprotein B in Parkinson’s Disease Patients. Wei, Qiang; Wang, Honghao; Tian, Yanghua; Xu, Fangcheng; Chen, Xianwen; Wang, Kai // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    Background:Previous studies have shown a lower incidence of stroke in Parkinson’s disease (PD) patients. The role of the lipids and lipoproteins as risk factors for stroke is uncertain in the lower prevalence of stroke in PD patients. Objectives:To explore the lipids and lipoproteins...

  • A Pooled Efficacy Analysis of Cerivastatin in the Treatment of Primary Hyperlipidaemia. Stein, E.; Schopen, U.; Catagay, M. // Clinical Drug Investigation;1999, Vol. 18 Issue 6, p433 

    Objective: A pooled analysis was performed to investigate the efficacy and tolerability of cerivastatin, a novel synthetic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) inhibitor, for the treatment of various subgroups of patients with primary hyperlipidaemia. Design and Setting: All...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics